Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Tuberculosis, Multidrug-Resistant | 119 | 2024 | 938 | 22.700 |
Why?
|
Antitubercular Agents | 121 | 2024 | 1390 | 14.900 |
Why?
|
Tuberculosis | 61 | 2024 | 2030 | 9.930 |
Why?
|
Mycobacterium tuberculosis | 42 | 2024 | 1931 | 5.320 |
Why?
|
Tuberculosis, Pulmonary | 24 | 2024 | 846 | 4.370 |
Why?
|
Rifampin | 26 | 2024 | 345 | 4.290 |
Why?
|
Nitroimidazoles | 17 | 2022 | 118 | 3.920 |
Why?
|
Oxazoles | 16 | 2022 | 199 | 3.420 |
Why?
|
Extensively Drug-Resistant Tuberculosis | 12 | 2021 | 86 | 2.900 |
Why?
|
Drug Resistance, Multiple, Bacterial | 11 | 2018 | 590 | 1.850 |
Why?
|
HIV Infections | 34 | 2024 | 17564 | 1.630 |
Why?
|
Contact Tracing | 4 | 2024 | 275 | 1.540 |
Why?
|
Rural Health Services | 6 | 2012 | 392 | 1.530 |
Why?
|
South Africa | 25 | 2024 | 1870 | 1.370 |
Why?
|
Isoniazid | 6 | 2022 | 288 | 1.340 |
Why?
|
Antibiotics, Antitubercular | 5 | 2021 | 99 | 1.240 |
Why?
|
Community Health Services | 7 | 2011 | 659 | 1.140 |
Why?
|
Health Services Accessibility | 18 | 2024 | 5510 | 1.090 |
Why?
|
AIDS-Related Opportunistic Infections | 4 | 2019 | 664 | 1.080 |
Why?
|
Qualitative Research | 12 | 2024 | 3115 | 1.050 |
Why?
|
Lesotho | 11 | 2012 | 73 | 0.980 |
Why?
|
Microbial Sensitivity Tests | 14 | 2023 | 1965 | 0.900 |
Why?
|
Humans | 208 | 2024 | 768451 | 0.820 |
Why?
|
Human Rights | 5 | 2021 | 312 | 0.790 |
Why?
|
National Health Programs | 3 | 2017 | 442 | 0.730 |
Why?
|
Long QT Syndrome | 2 | 2015 | 472 | 0.720 |
Why?
|
Drug Resistance, Bacterial | 3 | 2019 | 1064 | 0.700 |
Why?
|
Pyrazinamide | 3 | 2019 | 60 | 0.690 |
Why?
|
Latent Tuberculosis | 2 | 2022 | 224 | 0.690 |
Why?
|
Oxazolidinones | 2 | 2017 | 98 | 0.660 |
Why?
|
Social Stigma | 3 | 2024 | 785 | 0.650 |
Why?
|
Family Characteristics | 1 | 2024 | 1002 | 0.650 |
Why?
|
Pregnant Women | 2 | 2021 | 576 | 0.640 |
Why?
|
Health Personnel | 8 | 2024 | 3384 | 0.600 |
Why?
|
Medication Adherence | 7 | 2024 | 2190 | 0.580 |
Why?
|
Harm Reduction | 1 | 2018 | 144 | 0.560 |
Why?
|
Attitude to Health | 4 | 2020 | 2030 | 0.560 |
Why?
|
Program Evaluation | 5 | 2012 | 2508 | 0.560 |
Why?
|
Medically Underserved Area | 2 | 2011 | 266 | 0.540 |
Why?
|
Ethambutol | 2 | 2016 | 59 | 0.530 |
Why?
|
Anti-Retroviral Agents | 4 | 2024 | 1794 | 0.510 |
Why?
|
Georgia (Republic) | 6 | 2019 | 39 | 0.480 |
Why?
|
Child | 40 | 2024 | 80863 | 0.460 |
Why?
|
Microscopy | 1 | 2019 | 909 | 0.450 |
Why?
|
Peru | 16 | 2012 | 894 | 0.450 |
Why?
|
Aminosalicylic Acid | 1 | 2013 | 20 | 0.440 |
Why?
|
Tuberculin Test | 4 | 2022 | 205 | 0.430 |
Why?
|
Directly Observed Therapy | 7 | 2012 | 139 | 0.420 |
Why?
|
Delivery of Health Care | 5 | 2023 | 5367 | 0.410 |
Why?
|
Men's Health | 1 | 2012 | 75 | 0.400 |
Why?
|
Drug Therapy, Combination | 16 | 2024 | 6320 | 0.400 |
Why?
|
Social Support | 3 | 2020 | 2195 | 0.400 |
Why?
|
Breast Feeding | 1 | 2020 | 1365 | 0.390 |
Why?
|
Electrocardiography | 2 | 2015 | 6410 | 0.390 |
Why?
|
Medicine, African Traditional | 1 | 2011 | 31 | 0.380 |
Why?
|
Blood-Borne Pathogens | 1 | 2011 | 52 | 0.370 |
Why?
|
Diagnostic Tests, Routine | 1 | 2017 | 792 | 0.370 |
Why?
|
Universal Precautions | 1 | 2011 | 34 | 0.370 |
Why?
|
Prisoners | 3 | 2012 | 317 | 0.370 |
Why?
|
Sputum | 5 | 2019 | 511 | 0.370 |
Why?
|
Earthquakes | 1 | 2013 | 192 | 0.350 |
Why?
|
Drug Delivery Systems | 3 | 2021 | 2238 | 0.350 |
Why?
|
Mothers | 1 | 2020 | 2210 | 0.340 |
Why?
|
Patient-Centered Care | 5 | 2021 | 1439 | 0.330 |
Why?
|
Interviews as Topic | 6 | 2024 | 2733 | 0.330 |
Why?
|
Soccer | 1 | 2011 | 142 | 0.320 |
Why?
|
Adult | 54 | 2024 | 223542 | 0.320 |
Why?
|
Practice Guidelines as Topic | 4 | 2023 | 7451 | 0.320 |
Why?
|
Patient Satisfaction | 3 | 2020 | 3484 | 0.320 |
Why?
|
Female | 70 | 2024 | 396943 | 0.310 |
Why?
|
Drug Administration Schedule | 8 | 2024 | 4861 | 0.310 |
Why?
|
Professional Role | 1 | 2011 | 316 | 0.310 |
Why?
|
Mass Screening | 4 | 2020 | 5455 | 0.310 |
Why?
|
Disease Outbreaks | 3 | 2024 | 1764 | 0.300 |
Why?
|
Compassionate Use Trials | 3 | 2017 | 50 | 0.300 |
Why?
|
Quality of Health Care | 3 | 2019 | 4340 | 0.300 |
Why?
|
Drug Resistance, Multiple | 3 | 2007 | 255 | 0.300 |
Why?
|
Health Knowledge, Attitudes, Practice | 3 | 2015 | 4049 | 0.300 |
Why?
|
Treatment Outcome | 33 | 2024 | 65409 | 0.300 |
Why?
|
Patients | 1 | 2014 | 909 | 0.300 |
Why?
|
Haiti | 3 | 2018 | 553 | 0.300 |
Why?
|
Clinical Protocols | 5 | 2023 | 1444 | 0.300 |
Why?
|
Models, Organizational | 1 | 2011 | 546 | 0.290 |
Why?
|
Aviation | 1 | 2008 | 49 | 0.290 |
Why?
|
World Health Organization | 6 | 2019 | 1328 | 0.290 |
Why?
|
Epidemics | 1 | 2013 | 517 | 0.280 |
Why?
|
Disaster Planning | 1 | 2013 | 560 | 0.280 |
Why?
|
Nurse's Role | 2 | 2011 | 188 | 0.280 |
Why?
|
Transportation of Patients | 1 | 2008 | 176 | 0.270 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2012 | 614 | 0.270 |
Why?
|
Anti-HIV Agents | 3 | 2024 | 4567 | 0.270 |
Why?
|
India | 6 | 2024 | 2323 | 0.260 |
Why?
|
Adolescent | 35 | 2024 | 89168 | 0.260 |
Why?
|
Retrospective Studies | 39 | 2022 | 81834 | 0.260 |
Why?
|
Male | 60 | 2024 | 364781 | 0.260 |
Why?
|
Program Development | 6 | 2012 | 1296 | 0.260 |
Why?
|
Needs Assessment | 1 | 2011 | 1146 | 0.250 |
Why?
|
Infection Control | 3 | 2020 | 985 | 0.230 |
Why?
|
Hospitalization | 1 | 2024 | 10845 | 0.230 |
Why?
|
Time Factors | 15 | 2020 | 40271 | 0.230 |
Why?
|
Anti-Bacterial Agents | 3 | 2023 | 7471 | 0.220 |
Why?
|
Chemistry, Pharmaceutical | 2 | 2015 | 275 | 0.220 |
Why?
|
Community Health Nursing | 1 | 2003 | 23 | 0.220 |
Why?
|
Health Services Needs and Demand | 1 | 2011 | 1408 | 0.210 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2011 | 952 | 0.210 |
Why?
|
Tuberculosis, Meningeal | 1 | 2023 | 49 | 0.210 |
Why?
|
Occupational Diseases | 1 | 2011 | 1494 | 0.210 |
Why?
|
Research Design | 3 | 2019 | 6217 | 0.200 |
Why?
|
Russia | 7 | 2012 | 386 | 0.200 |
Why?
|
Social Environment | 1 | 2007 | 1026 | 0.200 |
Why?
|
Communicable Disease Control | 3 | 2020 | 857 | 0.200 |
Why?
|
Clinical Trials as Topic | 3 | 2023 | 8051 | 0.200 |
Why?
|
Corneal Ulcer | 1 | 2023 | 127 | 0.200 |
Why?
|
Antiretroviral Therapy, Highly Active | 3 | 2022 | 1903 | 0.190 |
Why?
|
Poverty | 6 | 2007 | 2719 | 0.190 |
Why?
|
Anthropology, Cultural | 2 | 2011 | 103 | 0.190 |
Why?
|
Social Justice | 2 | 2024 | 486 | 0.180 |
Why?
|
Health Policy | 2 | 2019 | 2699 | 0.180 |
Why?
|
Health Promotion | 1 | 2012 | 2215 | 0.180 |
Why?
|
Counseling | 3 | 2023 | 1548 | 0.180 |
Why?
|
Social Identification | 1 | 2020 | 108 | 0.170 |
Why?
|
Middle Aged | 25 | 2024 | 223418 | 0.170 |
Why?
|
Tuberculosis Vaccines | 1 | 2019 | 48 | 0.160 |
Why?
|
Internal Medicine | 2 | 2006 | 1056 | 0.160 |
Why?
|
Cooperative Behavior | 3 | 2011 | 1514 | 0.160 |
Why?
|
Developing Countries | 8 | 2012 | 2901 | 0.160 |
Why?
|
Young Adult | 16 | 2023 | 60045 | 0.160 |
Why?
|
Alcoholism | 1 | 2009 | 1993 | 0.160 |
Why?
|
Treatment Failure | 4 | 2019 | 2656 | 0.160 |
Why?
|
Pseudomonas Infections | 1 | 2023 | 623 | 0.160 |
Why?
|
Patient Acceptance of Health Care | 1 | 2012 | 3237 | 0.160 |
Why?
|
Infant | 9 | 2021 | 36497 | 0.150 |
Why?
|
Child, Preschool | 16 | 2024 | 42623 | 0.150 |
Why?
|
Pregnancy | 7 | 2023 | 30179 | 0.150 |
Why?
|
Schistosomiasis haematobia | 1 | 2017 | 15 | 0.150 |
Why?
|
Ethionamide | 1 | 2017 | 11 | 0.150 |
Why?
|
Decision Making | 1 | 2011 | 3961 | 0.150 |
Why?
|
Yogurt | 1 | 2017 | 71 | 0.140 |
Why?
|
Quality-Adjusted Life Years | 1 | 2024 | 1734 | 0.140 |
Why?
|
Disease Transmission, Infectious | 2 | 2020 | 562 | 0.140 |
Why?
|
Pulmonary Medicine | 1 | 2019 | 223 | 0.140 |
Why?
|
Anthelmintics | 1 | 2017 | 83 | 0.140 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2003 | 716 | 0.140 |
Why?
|
Cycloserine | 1 | 2017 | 118 | 0.140 |
Why?
|
Drug Resistance | 2 | 2021 | 1599 | 0.140 |
Why?
|
Football | 1 | 2022 | 507 | 0.140 |
Why?
|
Hyperbilirubinemia | 1 | 2016 | 74 | 0.130 |
Why?
|
Papua New Guinea | 1 | 2016 | 47 | 0.130 |
Why?
|
Drug Carriers | 1 | 2021 | 712 | 0.130 |
Why?
|
Predictive Value of Tests | 4 | 2014 | 15460 | 0.130 |
Why?
|
Europe, Eastern | 1 | 2016 | 72 | 0.130 |
Why?
|
Colony Count, Microbial | 1 | 2016 | 329 | 0.130 |
Why?
|
Self Care | 1 | 2021 | 798 | 0.130 |
Why?
|
Chi-Square Distribution | 2 | 2012 | 3438 | 0.130 |
Why?
|
Milk, Human | 1 | 2020 | 489 | 0.130 |
Why?
|
Costs and Cost Analysis | 1 | 2021 | 1670 | 0.130 |
Why?
|
Early Diagnosis | 1 | 2020 | 1196 | 0.120 |
Why?
|
Nanotechnology | 1 | 2021 | 714 | 0.120 |
Why?
|
Genome, Bacterial | 1 | 2020 | 798 | 0.120 |
Why?
|
Lung Diseases | 2 | 2024 | 1926 | 0.120 |
Why?
|
Cholecalciferol | 1 | 2020 | 557 | 0.120 |
Why?
|
Anemia | 1 | 2024 | 1521 | 0.120 |
Why?
|
Vaccination | 2 | 2019 | 3434 | 0.120 |
Why?
|
Case Management | 1 | 2016 | 276 | 0.120 |
Why?
|
Specimen Handling | 1 | 2019 | 709 | 0.120 |
Why?
|
Dentist-Patient Relations | 1 | 2014 | 30 | 0.120 |
Why?
|
Dental Care for Chronically Ill | 1 | 2014 | 31 | 0.120 |
Why?
|
Home Care Services | 1 | 2021 | 655 | 0.120 |
Why?
|
Pregnancy Complications, Infectious | 2 | 2005 | 2181 | 0.120 |
Why?
|
Stomach | 1 | 2019 | 703 | 0.120 |
Why?
|
Injections | 1 | 2017 | 840 | 0.120 |
Why?
|
Milk | 1 | 2017 | 445 | 0.120 |
Why?
|
Hypersensitivity | 1 | 2023 | 1172 | 0.110 |
Why?
|
Pharmaceutical Preparations | 2 | 2020 | 1089 | 0.110 |
Why?
|
Endpoint Determination | 1 | 2016 | 591 | 0.110 |
Why?
|
Dosage Forms | 1 | 2013 | 56 | 0.110 |
Why?
|
Complementary Therapies | 1 | 1997 | 487 | 0.110 |
Why?
|
Rural Population | 4 | 2017 | 2317 | 0.110 |
Why?
|
Education, Medical, Graduate | 1 | 2005 | 2411 | 0.110 |
Why?
|
Technology, Pharmaceutical | 1 | 2013 | 84 | 0.110 |
Why?
|
Risk Factors | 14 | 2024 | 74915 | 0.100 |
Why?
|
Cohort Studies | 10 | 2022 | 41797 | 0.100 |
Why?
|
Communicable Diseases | 1 | 2021 | 875 | 0.100 |
Why?
|
Internationality | 1 | 2018 | 1007 | 0.100 |
Why?
|
Patient Isolation | 1 | 2013 | 100 | 0.100 |
Why?
|
Stereotyping | 1 | 2014 | 243 | 0.100 |
Why?
|
Hospitals | 2 | 2023 | 3906 | 0.100 |
Why?
|
Diffusion of Innovation | 1 | 2017 | 730 | 0.100 |
Why?
|
Drug Approval | 2 | 2016 | 817 | 0.100 |
Why?
|
Geography | 1 | 2014 | 654 | 0.100 |
Why?
|
Risk Assessment | 6 | 2020 | 24311 | 0.100 |
Why?
|
Incidence | 7 | 2019 | 21552 | 0.100 |
Why?
|
Cost-Benefit Analysis | 2 | 2024 | 5532 | 0.100 |
Why?
|
Infertility, Female | 1 | 2017 | 764 | 0.100 |
Why?
|
Physicians | 1 | 2009 | 4615 | 0.100 |
Why?
|
Gloves, Protective | 1 | 2011 | 23 | 0.090 |
Why?
|
Consultants | 1 | 2011 | 57 | 0.090 |
Why?
|
Age Factors | 4 | 2019 | 18478 | 0.090 |
Why?
|
Healthcare Disparities | 4 | 2024 | 3412 | 0.090 |
Why?
|
Research | 1 | 2019 | 1984 | 0.090 |
Why?
|
Health Plan Implementation | 2 | 2011 | 338 | 0.090 |
Why?
|
Logistic Models | 6 | 2018 | 13324 | 0.090 |
Why?
|
Drug Combinations | 1 | 2016 | 2079 | 0.090 |
Why?
|
Siberia | 1 | 2009 | 30 | 0.090 |
Why?
|
Caregivers | 1 | 2022 | 2302 | 0.090 |
Why?
|
Hearing Loss | 1 | 2017 | 786 | 0.090 |
Why?
|
Organizational Case Studies | 2 | 2007 | 301 | 0.090 |
Why?
|
Waiting Lists | 1 | 2014 | 778 | 0.080 |
Why?
|
Aged | 13 | 2023 | 171520 | 0.080 |
Why?
|
Vulnerable Populations | 2 | 2015 | 717 | 0.080 |
Why?
|
Homosexuality, Male | 1 | 1997 | 1345 | 0.080 |
Why?
|
Health Care Surveys | 2 | 2009 | 2437 | 0.080 |
Why?
|
Organizational Objectives | 1 | 2011 | 427 | 0.080 |
Why?
|
International Cooperation | 1 | 2015 | 1439 | 0.080 |
Why?
|
Europe | 1 | 2016 | 3439 | 0.080 |
Why?
|
Cost of Illness | 2 | 2019 | 1960 | 0.080 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 1997 | 2203 | 0.080 |
Why?
|
Telemedicine | 3 | 2021 | 3104 | 0.080 |
Why?
|
Population Surveillance | 3 | 2019 | 2601 | 0.080 |
Why?
|
Culture | 1 | 2012 | 624 | 0.080 |
Why?
|
Financing, Personal | 1 | 2011 | 310 | 0.080 |
Why?
|
Thrombocytopenia | 1 | 2016 | 1183 | 0.080 |
Why?
|
Emigration and Immigration | 2 | 2004 | 405 | 0.080 |
Why?
|
Kidney Diseases | 1 | 2019 | 2102 | 0.080 |
Why?
|
Pneumonectomy | 1 | 2015 | 1159 | 0.080 |
Why?
|
Perception | 1 | 2014 | 1207 | 0.070 |
Why?
|
Dietary Supplements | 1 | 2020 | 3445 | 0.070 |
Why?
|
CD4 Lymphocyte Count | 1 | 2013 | 2596 | 0.070 |
Why?
|
Mental Health | 1 | 2021 | 3271 | 0.070 |
Why?
|
Quality of Life | 2 | 2021 | 13497 | 0.070 |
Why?
|
Air Ambulances | 1 | 2008 | 93 | 0.070 |
Why?
|
Public Health | 3 | 2024 | 2693 | 0.070 |
Why?
|
Policy | 2 | 2024 | 515 | 0.070 |
Why?
|
Internship and Residency | 2 | 2006 | 5952 | 0.070 |
Why?
|
Health Education | 1 | 2013 | 1059 | 0.070 |
Why?
|
Double-Blind Method | 1 | 2020 | 12450 | 0.060 |
Why?
|
Prevalence | 5 | 2019 | 15880 | 0.060 |
Why?
|
Mutation | 2 | 2020 | 30243 | 0.060 |
Why?
|
Disease Management | 2 | 2015 | 2533 | 0.060 |
Why?
|
Interprofessional Relations | 1 | 2011 | 997 | 0.060 |
Why?
|
Administration, Oral | 1 | 2013 | 4041 | 0.060 |
Why?
|
Burundi | 1 | 2024 | 12 | 0.060 |
Why?
|
Equipment Design | 1 | 2013 | 3530 | 0.060 |
Why?
|
Infant, Newborn | 3 | 2020 | 26395 | 0.060 |
Why?
|
Social Sciences | 1 | 2024 | 40 | 0.060 |
Why?
|
Moldova | 1 | 2024 | 14 | 0.060 |
Why?
|
Deafness | 2 | 2019 | 462 | 0.060 |
Why?
|
Pandemics | 2 | 2021 | 8753 | 0.050 |
Why?
|
Fatal Outcome | 1 | 2008 | 1840 | 0.050 |
Why?
|
Models, Educational | 1 | 2006 | 375 | 0.050 |
Why?
|
Community-Institutional Relations | 1 | 2004 | 208 | 0.050 |
Why?
|
Hypokalemia | 1 | 2004 | 153 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3116 | 0.050 |
Why?
|
Georgia | 1 | 2022 | 186 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3240 | 0.050 |
Why?
|
Alcohol Drinking | 2 | 2012 | 4052 | 0.050 |
Why?
|
Consensus | 2 | 2023 | 3207 | 0.050 |
Why?
|
Diagnosis, Differential | 2 | 2007 | 13026 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2019 | 10358 | 0.050 |
Why?
|
Malawi | 1 | 2022 | 308 | 0.050 |
Why?
|
Social Responsibility | 1 | 2004 | 385 | 0.050 |
Why?
|
Vitamin B 6 | 1 | 2022 | 234 | 0.050 |
Why?
|
Gram-Negative Bacteria | 1 | 2023 | 276 | 0.050 |
Why?
|
Health Behavior | 1 | 2012 | 2649 | 0.050 |
Why?
|
Brazil | 1 | 2024 | 1247 | 0.040 |
Why?
|
Prisons | 1 | 2022 | 178 | 0.040 |
Why?
|
Multivariate Analysis | 2 | 2012 | 12096 | 0.040 |
Why?
|
Cross-Sectional Studies | 3 | 2017 | 26351 | 0.040 |
Why?
|
Severity of Illness Index | 3 | 2018 | 15965 | 0.040 |
Why?
|
Mental Health Services | 1 | 2011 | 1732 | 0.040 |
Why?
|
Patient Care Team | 1 | 2011 | 2526 | 0.040 |
Why?
|
Nomograms | 1 | 2021 | 236 | 0.040 |
Why?
|
Drug and Narcotic Control | 1 | 2020 | 146 | 0.040 |
Why?
|
Age Distribution | 2 | 2003 | 2881 | 0.040 |
Why?
|
Political Systems | 1 | 2019 | 23 | 0.040 |
Why?
|
Molecular Epidemiology | 1 | 2021 | 473 | 0.040 |
Why?
|
Ventilators, Mechanical | 1 | 2021 | 292 | 0.040 |
Why?
|
Delphi Technique | 1 | 2023 | 879 | 0.040 |
Why?
|
House Calls | 1 | 2021 | 171 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2019 | 10784 | 0.040 |
Why?
|
Standard of Care | 1 | 2023 | 571 | 0.040 |
Why?
|
Methicillin Resistance | 1 | 1999 | 198 | 0.040 |
Why?
|
Sex Factors | 1 | 2012 | 10647 | 0.040 |
Why?
|
Armenia | 1 | 2018 | 16 | 0.040 |
Why?
|
Hospital Mortality | 1 | 2012 | 5371 | 0.040 |
Why?
|
Schistosoma haematobium | 1 | 2017 | 13 | 0.040 |
Why?
|
Masks | 1 | 2020 | 215 | 0.040 |
Why?
|
Biological Specimen Banks | 1 | 2023 | 783 | 0.040 |
Why?
|
Health Care Costs | 1 | 2011 | 3265 | 0.040 |
Why?
|
Sex Distribution | 1 | 2003 | 2286 | 0.040 |
Why?
|
Electromyography | 1 | 2003 | 1399 | 0.040 |
Why?
|
Socioeconomic Factors | 3 | 2007 | 7863 | 0.040 |
Why?
|
Social Conditions | 1 | 1997 | 121 | 0.040 |
Why?
|
Drug Stability | 1 | 2017 | 291 | 0.030 |
Why?
|
Doxycycline | 1 | 2019 | 348 | 0.030 |
Why?
|
Drug Resistance, Microbial | 1 | 2000 | 830 | 0.030 |
Why?
|
Biological Availability | 1 | 2017 | 390 | 0.030 |
Why?
|
Child Nutrition Disorders | 1 | 2018 | 140 | 0.030 |
Why?
|
Patient Compliance | 2 | 2006 | 2696 | 0.030 |
Why?
|
Child Nutritional Physiological Phenomena | 1 | 2018 | 294 | 0.030 |
Why?
|
Physician-Patient Relations | 1 | 2009 | 3267 | 0.030 |
Why?
|
Cultural Characteristics | 1 | 1997 | 250 | 0.030 |
Why?
|
Health Priorities | 1 | 2019 | 379 | 0.030 |
Why?
|
Adaptation, Psychological | 2 | 2022 | 2665 | 0.030 |
Why?
|
Activities of Daily Living | 1 | 2024 | 2433 | 0.030 |
Why?
|
Pseudomonas aeruginosa | 1 | 2023 | 1277 | 0.030 |
Why?
|
Delayed-Action Preparations | 1 | 2019 | 969 | 0.030 |
Why?
|
Follow-Up Studies | 4 | 2006 | 39430 | 0.030 |
Why?
|
Kenya | 1 | 2017 | 757 | 0.030 |
Why?
|
Boston | 1 | 2007 | 9361 | 0.030 |
Why?
|
Massachusetts | 2 | 2005 | 8908 | 0.030 |
Why?
|
HIV | 1 | 2021 | 1596 | 0.030 |
Why?
|
Goals | 1 | 2019 | 715 | 0.030 |
Why?
|
California | 1 | 1997 | 1444 | 0.030 |
Why?
|
Prenatal Exposure Delayed Effects | 1 | 2005 | 2538 | 0.030 |
Why?
|
Survival Analysis | 1 | 2005 | 10125 | 0.030 |
Why?
|
Adrenergic alpha-Agonists | 1 | 1993 | 177 | 0.020 |
Why?
|
Curriculum | 1 | 2006 | 3778 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2024 | 3590 | 0.020 |
Why?
|
BCG Vaccine | 1 | 2015 | 383 | 0.020 |
Why?
|
Proportional Hazards Models | 3 | 2014 | 12561 | 0.020 |
Why?
|
Malnutrition | 1 | 2018 | 632 | 0.020 |
Why?
|
Mental Disorders | 1 | 2011 | 6879 | 0.020 |
Why?
|
Protein-Energy Malnutrition | 1 | 2012 | 189 | 0.020 |
Why?
|
Endemic Diseases | 1 | 2012 | 191 | 0.020 |
Why?
|
False Negative Reactions | 1 | 2012 | 575 | 0.020 |
Why?
|
Age of Onset | 1 | 2018 | 3342 | 0.020 |
Why?
|
Prospective Studies | 2 | 2024 | 54914 | 0.020 |
Why?
|
Comorbidity | 2 | 2018 | 10601 | 0.020 |
Why?
|
Pregnancy Outcome | 1 | 2021 | 2959 | 0.020 |
Why?
|
Symporters | 1 | 1993 | 363 | 0.020 |
Why?
|
Confidentiality | 1 | 2014 | 606 | 0.020 |
Why?
|
Africa, Southern | 1 | 2009 | 60 | 0.020 |
Why?
|
Nutritional Status | 1 | 2018 | 1623 | 0.020 |
Why?
|
Leadership | 1 | 2019 | 1395 | 0.020 |
Why?
|
Demography | 1 | 2014 | 1643 | 0.020 |
Why?
|
Prognosis | 2 | 2012 | 30028 | 0.020 |
Why?
|
Nanoparticles | 1 | 2021 | 1986 | 0.020 |
Why?
|
Swine | 1 | 2019 | 5996 | 0.020 |
Why?
|
Data Collection | 1 | 1997 | 3329 | 0.020 |
Why?
|
Periodicals as Topic | 1 | 2019 | 1468 | 0.020 |
Why?
|
Arrhythmias, Cardiac | 1 | 2018 | 2258 | 0.020 |
Why?
|
Mortality | 1 | 2019 | 2917 | 0.020 |
Why?
|
HIV Seronegativity | 1 | 2008 | 211 | 0.020 |
Why?
|
Societies, Medical | 1 | 2019 | 3955 | 0.020 |
Why?
|
Aged, 80 and over | 1 | 2012 | 59680 | 0.020 |
Why?
|
Artificial Intelligence | 1 | 2021 | 2659 | 0.020 |
Why?
|
Imidazoles | 1 | 1993 | 1174 | 0.020 |
Why?
|
Trachea | 1 | 1993 | 1095 | 0.020 |
Why?
|
Drug Monitoring | 1 | 2012 | 964 | 0.020 |
Why?
|
Secondary Prevention | 1 | 2012 | 1479 | 0.020 |
Why?
|
Self Report | 1 | 2017 | 3771 | 0.020 |
Why?
|
Ambulatory Care Facilities | 1 | 2011 | 941 | 0.020 |
Why?
|
Ambulatory Care | 2 | 2008 | 2780 | 0.010 |
Why?
|
Capreomycin | 1 | 2004 | 14 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2013 | 6242 | 0.010 |
Why?
|
Retreatment | 1 | 2006 | 601 | 0.010 |
Why?
|
Pilot Projects | 1 | 2017 | 8730 | 0.010 |
Why?
|
International Educational Exchange | 1 | 2004 | 54 | 0.010 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2007 | 495 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2006 | 15880 | 0.010 |
Why?
|
Lung | 1 | 2021 | 10090 | 0.010 |
Why?
|
Animals | 4 | 2019 | 169418 | 0.010 |
Why?
|
Inservice Training | 1 | 2004 | 377 | 0.010 |
Why?
|
Drug Tolerance | 1 | 2003 | 367 | 0.010 |
Why?
|
Disease Progression | 1 | 2018 | 13655 | 0.010 |
Why?
|
United States | 2 | 2006 | 73121 | 0.010 |
Why?
|
Magnesium | 1 | 2004 | 816 | 0.010 |
Why?
|
Carrier Proteins | 1 | 1993 | 4948 | 0.010 |
Why?
|
Sampling Studies | 1 | 2000 | 617 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2021 | 20762 | 0.010 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 2005 | 1359 | 0.010 |
Why?
|
Health Planning | 1 | 1998 | 233 | 0.010 |
Why?
|
Algorithms | 1 | 2017 | 14158 | 0.010 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2009 | 4419 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2008 | 8559 | 0.010 |
Why?
|
Morals | 1 | 1998 | 289 | 0.010 |
Why?
|
Smoking | 1 | 2012 | 9099 | 0.010 |
Why?
|
Sodium Chloride Symporters | 1 | 1993 | 10 | 0.010 |
Why?
|
Imidazoline Receptors | 1 | 1993 | 13 | 0.010 |
Why?
|
Thromboxane-A Synthase | 1 | 1993 | 34 | 0.010 |
Why?
|
Guanabenz | 1 | 1993 | 6 | 0.010 |
Why?
|
Prazosin | 1 | 1993 | 95 | 0.010 |
Why?
|
Chloride-Bicarbonate Antiporters | 1 | 1993 | 103 | 0.010 |
Why?
|
Receptors, Adrenergic, alpha | 1 | 1993 | 146 | 0.010 |
Why?
|
Receptors, Drug | 1 | 1993 | 157 | 0.010 |
Why?
|
Isoproterenol | 1 | 1993 | 398 | 0.010 |
Why?
|
Second Messenger Systems | 1 | 1993 | 204 | 0.010 |
Why?
|
Clonidine | 1 | 1993 | 170 | 0.010 |
Why?
|
Iodine Radioisotopes | 1 | 1993 | 1035 | 0.010 |
Why?
|
Cyclic AMP | 1 | 1993 | 1468 | 0.000 |
Why?
|
Drug Interactions | 1 | 1993 | 1421 | 0.000 |
Why?
|
Epithelium | 1 | 1993 | 1610 | 0.000 |
Why?
|
Rabbits | 1 | 1993 | 4786 | 0.000 |
Why?
|
Antihypertensive Agents | 1 | 1993 | 2028 | 0.000 |
Why?
|
Epithelial Cells | 1 | 1993 | 3697 | 0.000 |
Why?
|
Cells, Cultured | 1 | 1993 | 19041 | 0.000 |
Why?
|